XHKG
6622
Market cap165mUSD
Oct 09, Last price
2.27HKD
1D
-4.22%
1Q
-14.34%
IPO
-81.84%
Name
Zhaoke Ophthalmology Ltd
Chart & performance
P/E
—
P/S
34.11
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.44%
Rev. gr., 5y
%
Revenues
31m
-55.07%
Net income
-204m
L-14.28%
CFO
-260m
L+2.55%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.
Key people
Xinyan Feng
Chief Financial Officer · since 2020
Lok Yee Li
Senior Vice President - Research and Development · since 2020
Lit Fui Lau
President, Chief Operating Officer, Chief Scientific Officer · since 2022
Lei Yang
General Counsel · since 2021
Suk Yan Yau
Financial Controller, Company Secretary · since 2019
Guohui Zhang
Deputy General Director · since 2016
Xiangrong Dai
Executive Director · since 2020
Xiaoyi Li
Executive Chairman, Chief Executive Officer · since 2017
Jiang Feng
Director of Sales, Director of Marketing · since 2020
Mauro Bove
Business Development Director · since 2019
Su Jiang
Clinical Operations Director · since 2019
Yixuan Jin
Associate Medical Director · since 2019
Carol Liu
Head of Regulatory Affairs · since 2021
Jian Ma
Assistance Manger of Quality Assurance and Quality Control · since 2018
Albert Tsai
Chief Medical Officer · since 2021
Zhijun Xie
Pre-Clinical Research and Development · since 2021
Non-Executive Director · since 2017
Wanee Leelalertsuphakun
Non-Executive Director · since 2017
Tiantian Zhang
Non-Executive Director · since 2021
Fui Kiang Liew
Independent Non-Executive Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||